"Addressing even one crore patients translates to a Rs 3,0004,000 crore opportunity," he says, "but the market will only expand meaningfully at lower price points, especially beyond metros." He expects the GLP-1 category to surpass Rs 2,000 crore within a year, led by generics driving down entry barriers
When an operator provides tutorials, demo modes, and responsive support channels, players can test options without pressure
Who Should Not Use a GLP-1 program
Michael White, professor of pharmacy practice at the University of Connecticut School of Pharmacy, is skeptical, to say the least: The marketing seems to suggest that you could get with these natural products, these natural ingredients, the same effect that you can get with GLP-1 agonists, which is simply not the case
This evolution has made it possible to connect with qualified medical providers from your own home, making specialized treatments like GLP-1 therapy more accessible than ever before
These combinations are largely untested in clinical trials